Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intervention in mild-to-moderate COPD with treatable traits
ChiCTR2500113245Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of BGF MDI HFO and tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Time to first clinically important deterioration (CID). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
BGF MDI HFOtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2500113245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113245.